pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

COMPANY OVERVIEW

OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease.

LOCATION

  • Rockville, MD, USA

    • THERAPEUTIC AREAS

  • Autoimmune Disease

  • Oncology

    • WEBSITE

    https://www.oncoimmune.com/

    CAREER WEBSITE

    None

    SOCIAL MEDIA

    INVESTORS

    3e-bioventures-capital

    PRESS RELEASES


    Nov 23, 2020

    Merck to Acquire OncoImmune


    Sep 24, 2020

    OncoImmune’s SACCOVID™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19


    Sep 23, 2020

    OncoImmune Launches First-in-human Clinical Trial for ONC-392 – The anti-CTLA-4 Antibody that Preserves CTLA4 Recycling for Safer and More Effective Immunotherapy


    Sep 9, 2020

    OncoImmune, Inc. Raises $56 Million Series B Financing for Novel Cancer and COVID-19 Therapeutics


    Jun 14, 2020

    OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19


    For More Press Releases
    Google Analytics Alternative